Atrial natriuretic peptide, a diuretic, natriuretic and vasorelaxant hormone, is also
involved in the regulation of cardiovascular remodeling and it has been recently shown to be significantly
associated with higher occurrence of cardiovascular diseases. In fact, high plasma
ANP levels predict higher mortality rate for cardiovascular events. Moreover, ANP gene alterations
are associated with higher risk of cardiovascular intermediate phenotypes, such as left
ventricular hypertrophy, and of cardiovascular diseases, such as stroke and hypertension.
Thus, the characterization of ANP plasma levels, and of ANP genotype for known mutations can
be proposed as an informative component of the individual cardiovascular risk profile. (Heart International
2006; 2: 78-81)
Atrial natriuretic peptide, Cardiovascular risk, Genetic
Speranza Rubattu, MD, IRCCS Neuromed, Località Camerelle-Zona Industriale, 86077 Pozzilli (IS) – Italy, rubattu.speranza@neuromed.it
Trending Topic
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1Â Recent estimates suggest that over 40% of these patients continue to have uncontrolled blood pressure (BP) and that […]
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.